Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology Times New Jersey.
Press releases published on September 22, 2025
Sonar Clarity (Avanoo) annonce une levée de fonds auprès d’Auriga Cyber Ventures pour lancer sa nouvelle stratégie de croissance en Europe
Sonar Clarity (Avanoo), éditeur d’une plateforme de SaaS Management qui aide les entreprises à reprendre le contrôle sur leur écosystème logiciel et IA, accueille Auriga Cyber Ventures dans son capital. Cette annonce s’inscrit dans un contexte de très …
SEALSQ and the Seoul Metropolitan Government Sign MoU to Establish a Post-Quantum Semiconductor Personalization, Research and Design Center in Seoul
Seoul, South Korea / Geneva, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- SEALSQ Corp (NASDAQ: LAES) ("SEALSQ" or "Company"), a company that focuses on developing and selling Semiconductors, PKI, and Post-Quantum technology hardware and software …
CellProthera announces peer-reviewed publication of its Phase I/IIb results on safety and feasibility of ProtheraCytes® in patients with severe heart failure post-myocardial Infarction
JACC-Heart Failure publication highlights high-quality cell expansion, good tolerability, manageable procedural risk and encouraging early signals of functional effects. Mulhouse, France – [DATE] – CellProthera today announced that its open-label …
CellProthera annonce la publication de ses résultats de phase I/IIb sur la sécurité et la faisabilité des ProtheraCytes® chez des patients souffrant d'insuffisance cardiaque sévère après un infarctus du myocarde.
La publication du JACC-Heart Failure souligne la haute qualité de l'expansion cellulaire, la bonne tolérance, le risque procédural gérable et les signes précoces encourageants d'effets fonctionnels. Mulhouse, France – 10 septembre 2025 - CellProthera a …
European Medicines Agency Recommends Marketing Authorization of AVT03, Alvotech’s Proposed Biosimilar to Prolia® and Xgeva®
REYKJAVIK, Iceland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that the European Medicines Agency’s ( …
First European Participants Randomized in AskBio Phase 2 Gene Therapy Trial of AB-1005 for Parkinson’s Disease
Research Triangle Park, N.C., Sept. 22, 2025 (GLOBE NEWSWIRE) -- AB-1005, a glial cell line-derived neurotrophic factor (GDNF) investigational gene therapy, is being evaluated for the treatment of moderate-stage Parkinson’s disease in the REGENERATE-PD …
Vocalbeats.AI Strengthens Commitment to AI Advancement as Sponsor of Singapore’s FutureChina Global Forum 2025
FutureChina Global Forum 2025 convened leaders from more than 25 countries, with Sponsor Vocalbeats.AI championing a future where artificial intelligence strengthens human connection. SINGAPORE, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Singapore AI innovation …
HKPC and GPTBots.ai: Joining Forces to Drive Intelligent Transformation for Hong Kong Enterprises
HONG KONG, Sept. 22, 2025 (GLOBE NEWSWIRE) -- GPTBots.ai, the enterprise AI platform of Aurora Mobile (NASDAQ: JG), co-hosted the highly anticipated thematic course "AI Agents Drive Intelligent Transformation" with the Hong Kong Productivity Council (HKPC …
Helio Diagnostics: A European CDMO dedicated to In Vitro Diagnostics
Helio Diagnostics: A European CDMO dedicated to In Vitro Diagnostics Helio Diagnostics is backed by a team with 25+ years of experience in the development and manufacturing of complex diagnostic devices. Marseille, France – September 22, 2025 – Helio …
European Medicines Agency Recommends Marketing Approval of Gobivaz®, Alvotech’s Proposed Biosimilar to Simponi® (golimumab) with Advanz Pharma as Commercialization Partner
REYKJAVIK, ICELAND and LONDON, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide and Advanz Pharma Holdco Limited (“Advanz …
Oculis Announces Presentation of Phase 2 ACUITY trial results with Privosegtor in Acute Optic Neuritis at ECTRIMS
ZUG, Switzerland, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on innovations for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, today …
BetaGlue Therapeutics Announces the Appointment of Alexis Peyroles as New Chief Executive Officer
MILAN, Sept. 22, 2025 (GLOBE NEWSWIRE) -- BetaGlue® Therapeutics (“BetaGlue” or the “Company”) a clinical-stage oncology company developing an innovative radiotherapy platform for the targeted and personalised treatment of unresectable solid tumours, …
ADC Innovator Myricx Bio Appoints Boston-based Mohit Rawat as CEO and Expands Team in US and UK
Mohit Rawat appointed CEO, bringing deep biopharma leadership and a track record of driving innovations in drug discovery to commercial and transactional success; former CEO Robin Carr transitions to new CTO role Expanded senior team across clinical, CMC, …
vivenu Introduces Native Resell Platform for Tickets
DÜSSELDORF, Germany, Sept. 22, 2025 (GLOBE NEWSWIRE) -- vivenu announced today the launch of its Native Resell Platform, a new feature that unifies primary and resale ticketing directly within organizers’ official shops and seat maps. The solution enables …
vivenu lance son Marché Secondaire pour les billets
DÜSSELDORF, Allemagne, 22 sept. 2025 (GLOBE NEWSWIRE) -- vivenu annonce aujourd’hui le lancement du vivenu Marché Secondaire, une fonctionnalité qui unifie billetterie primaire et revente directement dans la boutique officielle des organisateurs. La …
Trace One Appoints Séverine Tourpin as Chief Executive Officer
PARIS, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Trace One, a global leader in Product Lifecycle Management (PLM) and compliance solutions, announced today that Séverine Tourpin will serve as its new Chief Executive Officer, succeeding Christophe Vanackère. The …
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting
Two International Proxy Advisory Firms Support the Governance Project Proposed by OSE Immunotherapeutics at the September 30th General Meeting NANTES, France – September 22, 2025, 8:00 a.m. CET – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo: OSE) …
Opterion Health AG reicht Antrag auf klinische Studie für die erste Anwendung von OPT101 bei Patienten mit fortgeschrittener chronischer Nierenerkrankung ein
MUTTENZ, Schweiz, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Die Opterion Health AG, ein biopharmazeutisches Unternehmen im klinischen Stadium, das OPT101 als innovative Behandlung für Patienten unter Peritonealdialyse (PD) entwickelt, gab heute die Einreichung …
Deux agences internationales de conseil en vote soutiennent le projet de gouvernance proposé par OSE Immunotherapeutics à l’Assemblée Générale du 30 septembre
Deux agences internationales de conseil en vote soutiennent le projet de gouvernance proposé par OSE Immunotherapeutics à l’Assemblée Générale du 30 septembre NANTES, France – 22 septembre 2025, 8 h 00 – OSE Immunotherapeutics SA (ISIN: FR0012127173; Mnemo …